Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Rob van der Pluijm presented encouraging findings from TRAC II trial analyses of Triple Artemisinin Combination Therapies to the All-Party Parliamentary Group on Malaria & NTDs on March 19th in Westminster at the Houses of Parliament.

Rob van der Pluijm in Westminster © Credit: Andrea Stewart

Did you know? In the UK, members of parliament (MPs) from different political parties form All-Party Parliamentary Groups to discuss themes of particular importance to the UK government and its populace.

The APPG on malaria and NTDs gathered March 19 in Westminster; Jeremy Lefroy MP welcomed Rob van der Pluijm on behalf of MORU, the Tracking Resistance to Artemesinin Collaboration II and the Developing Triple Artemisinin-based Combination Therapies (DeTACT) Project.

Rob presented encouraging findings from TRAC II and launch plans for DeTACT in Africa and Asia. The UK Department for International Development’s (DfID) Senior Global Health Advisor attended alongside colleagues from the Wellcome Trust, LSHTM, Imperial College and other malaria advocacy groups.

Pertinent questions included whether DeTACT was an innovative attempt at ‘global health preparedness’ for eventual drug resistance in Africa; whether the WHO and national health programmes in endemic countries were likely to recommend triple dose treatments soon enough to prevent or slow the impact of drug resistance; and how well Mefloquine was tolerated when part of the Triple ACT combination.

Read a summary of the Westminster event.

Photo: APPG on Malaria & NTDs Chair Jeremy Lefroy MP (right) and Catherine West MP (second right), together with Rob van der Pluijm (centre) and other research presenters from LSHTM and Nottingham University. Text and photo credit: Andrea Stewart.

Similar stories

New SMRU building opened in Thailand to provide health care to marginalized populations

The inauguration of a new joint Shoklo Malaria Research Unit (SMRU) and Borderland Health Foundation (BHF) Building took place in Mae Ramat, Thailand, this week.

Constant genetic surveillance necessary to keep multidrug-resistant malaria parasite strains in check, study finds

Continually monitoring malaria parasite populations is necessary to prevent outbreaks of previously dormant multidrug-resistant malaria strains, say University of Oxford researchers. Multidrug-resistant malaria parasite strains can rapidly grow or collapse in response to public health policy changes, say the researchers in a study published today in The Lancet.

Meta-analysis informed the updated WHO guidelines for treatment of uncomplicated malaria in the first trimester of pregnancy

A new WWARN meta-analysis, commissioned by the World Health Organization and which informed a change to its treatment guidelines, has been published in The Lancet. The study provides compelling evidence that artemether-lumefantrine should now replace quinine as the treatment of choice in the first trimester.

Bacterial infections linked to one in eight global deaths, according to GRAM study

Data showing 7.7 million deaths from 33 bacterial infections can guide measures to strengthen health systems, particularly in low-income settings

GRAM visualization tool tracks country-level AMR and related metrics

Interactive app allows users to explore data underlying estimates of global AMR burden

MQRG team delivers training in Mozambique and Ghana

IDDO’s Medicine Quality Research Group delivered in-person training in researchers in Mozambique and Ghana to support a study into the quality of three antibiotics.